Navigation Links
Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
Date:6/1/2009

consider, including its Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; its annual report on Form 10-K filed with the SEC on October 30, 2008, as amended by that Form 10-K/A filed with the SEC on December 23, 2008; and its Form 10-Q filed with the SEC on April 13, 2009, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements.

For more information, please contact:

    Karl Cahill, Investor Relations
    (858) 531-6100
    kcahill@raptorpharma.com

    The Ruth Group
    Sara Ephraim Pellegrino (investors) / Janine McCargo (media)
    (646) 536-7002 / (646) 536-7033
    spellegrino@theruthgroup.com / jmccargo@theruthgroup.com


'/>"/>
SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
2. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
3. Raptor Pharmaceuticals Closes $10 Million Private Placement
4. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
5. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
6. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
8. Raptor Pharmaceuticals Acquires Orphan Clinical Program
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 16, 2014 “Never say, ‘I ... Universität Marburg’s Department of Physics, advises young women ... newly released SPIE Women in Optics 18-month ... shy to ask questions.” , In the annual ... mathematics) occupations ranging from university professor and laboratory ...
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
(Date:12/17/2014)... This report is a professional ... For an overview analysis, the report introduces quartz ... structure, industry overview, policy analysis, and news analysis, ... has witnessed rapid development with key manufacturers increasing ... report mentions quartz tubing upstream raw materials and ...
(Date:12/17/2014)... December 17, 2014 Gene synthesis ... it has entered into a technology access and ... to apply DNA2.0’s proprietary protein engineering technology, known ... , “We are extremely excited that the global ... This proprietary bioengineering technology has now been ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY ) (TSX: ONY) ... basic and diluted share, for the three months ended June 30, ... per basic and diluted share, for the comparable period in 2008. ... months ended June 30, 2009 for the change in the fair ...
... , , , ... Accera, Inc., a biotechnology company delivering breakthrough therapies in central ... paper in the peer-reviewed journal Nutrition & Metabolism . ... mild to moderate Alzheimer,s disease: a randomized, double-blind, placebo-controlled, multicenter ...
... , , , ... Cempra Pharmaceuticals today announced the appointment of John H. ... of Eli Lilly and Company, to the company,s Board of ... executive and operational management experience, including leadership of successful anti-infective ...
Cached Biology Technology:Oncothyreon reports second quarter 2009 financial results 2Oncothyreon reports second quarter 2009 financial results 3Oncothyreon reports second quarter 2009 financial results 4Oncothyreon reports second quarter 2009 financial results 5Oncothyreon reports second quarter 2009 financial results 6Oncothyreon reports second quarter 2009 financial results 7Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona(TM) ) in Mild to Moderate Alzheimer's Disease 2Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona(TM) ) in Mild to Moderate Alzheimer's Disease 3Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors 2Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors 3
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Materials engineers have created a new type of membrane ... be used for environmental cleanup, water purification and industrial ... conventional filters for separating oil from water and works ... usually mutually exclusive. Researchers attached the material to a ...
... the Netherlands Royal Academy of Arts and Sciences (KNAW) ... a new research programme: the Joint Scientific Thematic Research ... and the Academy will work together on developing bilateral ... and the Academy launched the joint research programme during ...
... Journal of Preventive Medicine special issue on climate ... Climate Changing People" conference today in Los Angeles. ... MD, DrPH, speaking about the impacts of climate change ... public health challenge. Health professionals need to understand the ...
Cached Biology News:New filtering technology has environmental, industrial applications 2New filtering technology has environmental, industrial applications 3NWO and Academy launch research program with China 2Issues at intersection of climate change and health impact global well-being 2Issues at intersection of climate change and health impact global well-being 3Issues at intersection of climate change and health impact global well-being 4
APG5 autophagy 5-like (S. cerevisiae)...
Human Jagged 2 Biotinylated Affinity Purified PAb...
Mouse/Rat WNK1 Affinity Purified Polyclonal Ab...
Griess Reagent component for determination of nitrite in aqueous solutions....
Biology Products: